source
- Rezdiffra Beats Wall Street Forecasts as MASH Market ExpandsRezdiffra, a drug candidate targeting metabolic dysfunction‑associated steatohepatitis (MASH), is outperforming analysts' expectations according to recent commentary. The optimism comes as the mar…
- Daiichi Sankyo targets $15 billion in oncology sales by 2030 as it expands ADC franchiseDaiichi Sankyo released a new five‑year business plan that sets a goal of nearly $15 billion in oncology revenue by 2030. The target is part of a broader ambition to push total company sales past 3…